Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Nishio M.

Lung Cancer. 2019 Jul;133:4-9. doi: 10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27.

PMID:
31200826
2.

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Kawashima Y, Nishikawa S, Ninomiya H, Yoshida R, Takano N, Oguri T, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ishikawa Y, Nishio M.

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

3.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.

Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.

PMID:
31027701
4.

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R.

J Exp Med. 2019 Apr 1;216(4):982-1000. doi: 10.1084/jem.20180870. Epub 2019 Mar 14.

5.

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.

Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8.

PMID:
30737231
6.

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T.

Clin Lung Cancer. 2019 May;20(3):e317-e328. doi: 10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31.

7.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
8.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R.

EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17.

9.

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.

Sonoda T, Nishikawa S, Sakakibara R, Saiki M, Ariyasu R, Koyama J, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ninomiya H, Ishikawa Y, Nishio M.

Respir Med Case Rep. 2018 Mar 16;24:19-21. doi: 10.1016/j.rmcr.2018.03.009. eCollection 2018.

10.

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.

Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M.

Clin Lung Cancer. 2018 Sep;19(5):435-440.e1. doi: 10.1016/j.cllc.2018.04.006. Epub 2018 May 10.

PMID:
29885946
11.

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R.

Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4.

PMID:
29496249
12.

Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M.

Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.

PMID:
28977547
13.

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.

Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M.

Anticancer Res. 2017 Aug;37(8):4229-4232.

PMID:
28739711
14.

Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer.

Kaira K, Yanagitani N, Sunaga N, Imai H, Ono A, Koga Y, Hisada T, Ishizuka T, Yamada M.

Oncol Lett. 2017 Jul;14(1):1123-1128. doi: 10.3892/ol.2017.6259. Epub 2017 May 26.

15.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.

Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, Kawashima Y, Takano N, Oguri T, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Nishio M.

Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.

PMID:
28225456
16.

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.

Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y.

Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22.

PMID:
28111119
17.

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.

Nishikawa S, Tambo Y, Ninomiya H, Oguri T, Kawashima Y, Takano N, Kitazono S, Ohyanagi F, Horiike A, Yanagitani N, Ishikawa Y, Nishio M.

Ann Oncol. 2016 Dec;27(12):2300-2302. doi: 10.1093/annonc/mdw431. Epub 2016 Oct 19. No abstract available.

PMID:
27760736
18.

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M.

Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27.

PMID:
27565810
19.

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M.

Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.

PMID:
26898613
20.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.

EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

21.

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, Horiike A, Yanagitani N, Ohyanagi F, Nishio M.

Cancer Sci. 2015 Nov;106(11):1554-60. doi: 10.1111/cas.12771. Epub 2015 Oct 7.

22.

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.

Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.

PMID:
25777467
23.

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Tanaka H, Horiike A, Sakatani T, Saito R, Yanagitani N, Kudo K, Ohyanagi F, Horai T, Nishio M.

Anticancer Drugs. 2015 Jun;26(5):573-8. doi: 10.1097/CAD.0000000000000220.

PMID:
25714250
24.

Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.

Ohyanagi F, Yanagitani N, Kudo K, Kawano Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S, Horai T, Nishio M.

Anticancer Res. 2014 Sep;34(9):5153-8.

PMID:
25202107
25.

Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk.

Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, Nagashima T, Ohtaki Y, Kaira K, Sunaga N, Yanagitani N, Yoshino R, Tsunekawa K, Igai H, Kamiyoshihara M, Usui K, Lezhava A, Tomizawa Y, Ishikawa T, Murakami M, Hayashizaki Y, Takeyoshi I.

Biomed Rep. 2014 Sep;2(5):719-724. Epub 2014 Jun 26.

26.

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma.

Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M.

Inflamm Res. 2014 Sep;63(9):789-96. doi: 10.1007/s00011-014-0753-1. Epub 2014 Jul 8.

PMID:
25001341
27.

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M.

Anticancer Res. 2014 Apr;34(4):1975-81.

PMID:
24692734
28.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.

Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.

29.

A phase II study of S-1 in relapsed small cell lung cancer.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M.

Mol Clin Oncol. 2013 Mar;1(2):263-266. Epub 2013 Jan 14.

30.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
31.

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K.

Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1.

32.

Elemental analysis of lung tissue particles and intracellular iron content of alveolar macrophages in pulmonary alveolar proteinosis.

Shimizu Y, Matsuzaki S, Dobashi K, Yanagitani N, Satoh T, Koka M, Yokoyama A, Ohkubo T, Ishii Y, Kamiya T, Mori M.

Respir Res. 2011 Jun 30;12:88. doi: 10.1186/1465-9921-12-88.

33.

[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].

Yanagitani N, Horiike A, Kudo K, Ohyanagi F, Nishio M, Horai T.

Nihon Kokyuki Gakkai Zasshi. 2011 Apr;49(4):282-6. Japanese.

PMID:
21591457
34.

Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Yanagitani N, Hoshi R, Satoh Y, Motoi N, Hamanaka W, Ishikawa Y, Mun M, Sakao Y, Okumura S, Nakagawa K, Horai T, Nishio M.

Lung Cancer. 2011 Dec;74(3):401-4. doi: 10.1016/j.lungcan.2011.03.019. Epub 2011 Apr 29.

PMID:
21529988
35.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

36.

Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.

Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y.

Anticancer Res. 2010 Dec;30(12):4819-28.

PMID:
21187458
37.

Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer.

Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K.

Nucl Med Biol. 2010 Nov;37(8):911-6. doi: 10.1016/j.nucmedbio.2010.06.004. Epub 2010 Jul 24.

PMID:
21055621
38.

Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.

Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Mori M, Endo K.

AJR Am J Roentgenol. 2010 Nov;195(5):1204-11. doi: 10.2214/AJR.09.4167.

PMID:
20966329
39.

Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M.

Exp Ther Med. 2010 Sep;1(5):799-808. Epub 2010 Jul 20.

40.

Decreased interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis.

Shimizu Y, Dobashi K, Endou K, Ono A, Yanagitani N, Utsugi M, Sano T, Ishizuka T, Shimizu K, Tanaka S, Mori M.

Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):449-61.

PMID:
20646340
41.

Eosinophilic bronchiolitis indicating eosinophilic airway disease with overexpression of carcinoembryonic antigen in sinus and bronchiole: case report.

Yanagitani N, Shimizu Y, Kazama T, Dobashi K, Ishizuka T, Mori M.

J Biol Regul Homeost Agents. 2010 Jan-Mar;24(1):99-102.

PMID:
20385076
42.

Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer.

Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N, Horiguchi K, Yamada M, Mori M.

Ann Surg Oncol. 2010 Aug;17(8):2222-8. doi: 10.1245/s10434-010-0956-9. Epub 2010 Feb 13.

PMID:
20155399
43.

Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes.

Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, Goto K, Ohe Y, Nishiwaki Y, Kuchiba A, Yamamoto S, Hirose H, Oka A, Yanagitani N, Saito R, Inoko H, Yokota J.

Carcinogenesis. 2010 May;31(5):834-41. doi: 10.1093/carcin/bgq003. Epub 2010 Jan 8.

PMID:
20061363
44.

[A case of neurosarcoidosis discovered in a patient complaining of chest pain].

Yanagitani N, Kotake M, Ishizuka T, Iwasaki Y, Sunaga N, Mori M.

Nihon Kokyuki Gakkai Zasshi. 2009 Dec;47(12):1087-92. Japanese.

PMID:
20058684
45.

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M.

Lung Cancer. 2010 Jul;69(1):99-104. doi: 10.1016/j.lungcan.2009.09.012. Epub 2009 Oct 23.

PMID:
19853960
46.

18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K.

J Nucl Med. 2009 Nov;50(11):1770-6. doi: 10.2967/jnumed.109.066837. Epub 2009 Oct 16.

47.

Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.

Yanagitani N, Kaira K, Ishizuka T, Aoki H, Utsugi M, Shimizu Y, Sunaga N, Endou K, Hisada T, Mori M.

Cases J. 2009 May 29;2:6910. doi: 10.1186/1757-1626-2-6910.

48.

CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M.

Ann Surg Oncol. 2009 Dec;16(12):3473-81. doi: 10.1245/s10434-009-0685-0. Epub 2009 Sep 24.

PMID:
19777189
49.

L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.

Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M.

Histopathology. 2009 Jun;54(7):804-13. doi: 10.1111/j.1365-2559.2009.03300.x.

PMID:
19635099
50.

Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M.

Lung Cancer. 2010 May;68(2):253-7. doi: 10.1016/j.lungcan.2009.06.024. Epub 2009 Jul 23.

PMID:
19631403

Supplemental Content

Loading ...
Support Center